Immuron Limited · ASX:IMC
Immuron — Investor Presentation (August 2017)
10 slides from Immuron's investor presentation, Aug 7, 2017
Slide 1: Immuron Limited
www.immuron.com: @ Immuron Limited Developing Therapies that Fundamentally Change the Paradigms of Care July 2017
Slide 2: Oral Immunotherapy: Scalable, Disruptive Technology
Oral Immunotherapy: Scalable, Disruptive © Technology Vaccines Are Antibodies Are Harvested Broad Therapeutic Effect Developed from Colostrum Induction of + Reduced gut and blood pathogens regulatory responsible forintating sy infammation + Reduces systemic inflammation of + Lowers organ injury Clea
Slide 3: NASH (Non-Alcoholic Fatty Liver) Pathophysiology
NASH (Non-Alcoholic Fatty Liver) Pathophysiology NASH - Pathophysiology © “Source Adbtes tom Cohen tay: Seat. no, 2011 + Blood derived antigens {including circulating LPS) determines tolerance vs. inflammation + Kupffer cells play a key role in liver inflammation and fibrosis + Tregs hold a key role
Slide 4: IMM-124E in NASH (Non-Alcoholic Fatty Liver)
IMM-124E in NASH (Non-Alcoholic Fatty Liver) © * Targeted antibodies mediate broad anti-inflammatory mechanism of action - Upstream Effect: LPS-TLR4 pathway - Downstream: Anti-inflammatory through both innate and adaptive immune systems (e.g., the induction of regulatory T-cells to control and inhib
Slide 5: IMM-124E - Summary of Data
IMM-124E - Summary of Data © 3 Prevention of Fibrosis and Improvement in Metabolic & Inflammatory Mark + Carbon-Tetrachloride (CCI4) a non-disease related fibrosis model + Aim: To demonstrate effects of IMM-124E on Fibrosis caused by Intraperitoneal CCl4 + Results: - Marked reduction in Liver Fibros
Slide 6: IMM-124E in NASH (Non-Alcoholic Fatty Liver)
IMM-124E in NASH (Non-Alcoholic Fatty Liver) © + Intestinal LPS | + Intestinal Permeability | + Tolerance — Activation of Innate system to suppress inflammation (NKT, DC, macrophages) + Insulin resistance | + Circulating LPS |
Slide 7: IMM-124E: Fatty-Liver Portfolio — Phase II Trials
IMM-124E: Fatty-Liver Portfolio — 3 Phase II © Trials SH and Pediatric NAFLD Three Ongoing Phase 2 Programs: NASI + Lead Principal Investigator: Arun Sanyal; Former President of AASLD (American Association for the Study of Liver Diseases) and current Chair of the Liver Study Section at the NIH (Nati
Slide 8: IMM-124E: NASH Phase II Trial
IMM-124E: NASH Phase II Trial IMM-124E-2001 Interim Analy: Patient Populations — No Safety Issues Reported + The study has 12 scheduled visits over the study duration of 28 weeks (24 weeks treatment and 4 weeks follow-up. The interim analysis was triggered when 80 patients (two thirds ofthe planned
Slide 9: Phase II: Interim Analysis Report - Improves Liver Function
Phase II: Interim Analysis Report - Improves Liver Function Box plot for predicted ALT AUC from ANCOVA (FAS population) Improved Liver Enzymes Prodited vale for ALT AUC 200 ane Analysis showed that the 1200 mg treatment group approached a significant difference to Placebo and that a dose effect beca
Slide 10: Thank You
Thank You ——— i